Utility of SOX6 and DAB2 for the Diagnosis of Malignant Mesothelioma
Authors:
- 29 March 2021
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 45 (9) , 1245-1251
Abstract
The separation of malignant mesothelioma from non–small cell lung carcinomas can be a difficult problem. Sex-determining region Y box 6 (SOX6) and disabled homolog 2 (DAB2) have recently been proposed as sensitive/specific markers of mesothelial lineage, but have not yet been independently tested for utility in mesothelioma diagnosis. Using tissue microarrays containing mesotheliomas (epithelioid: n=40, sarcomatoid: n=23) and non–small cell lung carcinomas (adenocarcinoma: n=52, squamous cell carcinoma: n=57, large cell carcinoma: n=12) we evaluated the performance of SOX6 and DAB2 by themselves, in conjunction with other established mesothelioma markers (calretinin, WT1, D2-40, CK5/6, HEG1) and combined with 3 broad-spectrum established carcinoma markers: claudin-4, MOC31, and BerEP4. For epithelioid mesothelioma, SOX6 and DAB2 had sensitivities of 85% and 98%, respectively. For sarcomatoid mesothelioma, SOX6 had a sensitivity of 13% and DAB2 could not be assessed due to background stromal staining. For SOX6 alone, specificity for mesothelioma versus adenocarcinoma, squamous cell carcinoma, and large cell carcinoma was 94%, 79%, and 92%, respectively, while for DAB2 specificity was 77%, 86%, and 67%. Combinations of SOX6 and established mesothelioma markers produced sensitivities of 95% or greater. A combination of SOX6 positive/claudin-4 negative staining was 95% to 100% specific for mesothelioma versus carcinoma with a sensitivity of 85%. SOX6 is a promising marker for the diagnosis of mesothelioma and potentially could be combined with other mesothelial markers or a broad-spectrum carcinoma marker to reach an accurate diagnosis with relatively few immunostains, The relatively low specificity and difficulty of interpreting DAB2 staining limits its utility for mesothelioma diagnosis.Keywords
This publication has 12 references indexed in Scilit:
- Claudin-4 shows superior specificity for mesothelioma vs non–small-cell lung carcinoma compared with MOC-31 and Ber-EP4Human Pathology, 2020
- HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant MesotheliomaAmerican Journal of Surgical Pathology, 2020
- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest GroupArchives of Pathology & Laboratory Medicine, 2018
- Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary AdenocarcinomaAmerican Journal of Surgical Pathology, 2017
- HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesotheliomaScientific Reports, 2017
- Value of Calretinin Immunostaining in Diagnostic PathologyApplied Immunohistochemistry & Molecular Morphology, 2014
- Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinomaCancer Epidemiology, 2013
- Characterization of Tumor-Suppressive Function of SOX6 in Human Esophageal Squamous Cell CarcinomaClinical Cancer Research, 2011
- The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative studyLaboratory Investigation, 2006
- Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesotheliomaLaboratory Investigation, 2005